The Most Important Angiogenic Growth Factors Influencing the Development and Function of Blood Vessels - in the Context of Coronary Artery Bypass Grafting (CABG)

[1] ABRAMOV D, EREZ E, DAGAN O, ABRAMOV Y, PEARL E, VEENA G, KATZ J, VIDNE BA, BARAK V. Increased levels of basic fibroblast growth factors are found in the cross-clamped heart during cardiopulmonary bypass. Can J Cardiol 2000; 16:313-318Search in Google Scholar

[2] ALVAREZ R, KANTARJIAN HM, CORTES JE. Biology of plateled-derived growth factor and its involvment in disease. Mayo Clin Proc 2006; 81:1241-125710.4065/81.9.1241Open DOISearch in Google Scholar

[3] ATTARAN S, SHERWOOD R, DASTIDAR MG, EL-GAMEL A. Identification of low circulatory transforming growth factor β-1 in patients with degenerative heart valce disease. Interact Cardiovasc Thorac Surg 2010; 11;791-79310.1510/icvts.2010.244384Search in Google Scholar

[4] BATES DO, HILLMAN NJ, WILLIAMS BJ, NEAL CR, POCOCK TM. Regulation of microvascular permeability by vascular endothelial growth factors. Anat 2002; 200:581-59710.1046/j.1469-7580.2002.00066.xSearch in Google Scholar

[5] BATTEGAY EJ, RAINES EW, SEIFERT RA, BOWEN-POPE DF, ROSS R. TGF-beta induces bimodal proliferation of connective tissue cells via complex control pf an autocrine PDGF loop. Cell 1990; 63:515-52410.1016/0092-8674(90)90448-NOpen DOISearch in Google Scholar

[6] BATTEGAY EJ, RUPP J, IRUELA-ARISPE L, SAGE EH, PECH M. PDGF-BB modulates endothelial proliferation and angiogenesis in vitro via PDGF-beta recxeptors. J Cell Biol 1994; 125:917-92810.1083/jcb.125.4.917Search in Google Scholar

[7] BERNOTAT-DANIELOWSKI S, SHARMA HS, SCHOTT RJ, SCHAPER W. Generation and localization of monoclonal antibodies against fibroblast growth factors in ischaemic collateralized porcine myocardium. Cardiovasc Res 1993; 27:1220-122810.1093/cvr/27.7.1220Open DOISearch in Google Scholar

[8] BERSE B, BROWN LF, VAN DE WATER L, DVORAK HF, SENGER DR. Vascular permeability factor (vascular endothelial factor) gene is expressed differentially in normal tissues, macrophages, and tumors. Mol Biol Cell. 1992; 3:211-2010.1091/mbc.3.2.211Open DOISearch in Google Scholar

[9] BRANTON MH, KOPP JB. TGF-β and fibrosis. Microbes Infect 1999; 1:1349-136510.1016/S1286-4579(99)00250-610611762Open DOISearch in Google Scholar

[10] BURTON PBJ, OWEN VJ, HAFIZI S, BARTON PJR, CARR-WHITE G, KOH T, DE SOUZA A, YACOUB MH, PEPPER JR. Vascular endothelial growth factor release following coronary artery bypass surgery: extracorporeal circulation versus beating heart surgery. Eur Heart J 2000; 21:1708-171310.1053/euhj.2000.217711032698Open DOISearch in Google Scholar

[11] CASSCELLS W, SPEIR E, SASSE J, KLAGSBRUN M, ALLEN P, LEE M, CALVO B, CHIBA M, HAGGROTH L, FOLKMAN J, et al. Isolation, characterization, and localization of heparin-binding growth factors in the heart. J Clin Invest 1990; 85:433-44110.1172/JCI1144562964422298919Open DOISearch in Google Scholar

[12] CLAFFEY KP, ABRAMS KRISTIN, SHIH SC, BROWN LF, MULLEN A, KEOUGH M. Fibroblast growth factor 2 activation of stromal cell vascular endothelial growth factor expression and angiogenesis. Lab Invest 2001; 81:61-7510.1038/labinvest.3780212Open DOISearch in Google Scholar

[13] CLAUSS M, GERLACH M, GERLACH H, BRETT J, WANG F, FAMILLETTI PC, PAN Y-C, OLANDER JV, CONNOLLY DT, STERN D. Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med 1990; 172:1535-154510.1084/jem.172.6.1535Search in Google Scholar

[14] DAVIS S, ALDRICH TH, JONES PF, ACHESON A, COMPTON DL, JAIN V, RYAN TE, BRUNO J, RADZIEJEWSKI C, MAISONPIERRE PC, YANCOPOULOS GD. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 1996; 87: 1161-116910.1016/S0092-8674(00)81812-7Search in Google Scholar

[15] DĄBEK J, KUŁACH A, MONASTYRSKA-CUP B, GĄSIOR Z. Transforming growth factor β and cardiovascular diseases: the other facet of the „protective cytokine“. Pharmacol Rep 2006; 58:799-805Search in Google Scholar

[16] DENIZOT Y, GUGLIELMI L, CORNU E, NATHAN N. Alterations in plasma angiogenic growth factor concentrations after coronary artery bypass graft surgery: relationships with post-operative complications. Cytokine 2003; 24:7-1210.1016/S1043-4666(03)00241-2Open DOISearch in Google Scholar

[17] DIMMELER S, DERNBACH E, ZEIHER AM. Phosphorylation of the endothelial nitric oxide synthase at ser-1177 is required for VEGF-induced endothelial cell migration. FEBS Lett 2000; 477:258-26210.1016/S0014-5793(00)01657-4Search in Google Scholar

[18] DVORAK HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002;20:4368-438010.1200/JCO.2002.10.08812409337Open DOISearch in Google Scholar

[19] FARNEBO F, PIEHL F, LAGERCRANTZ J. Restricted expression pattern of vegf-d in the adult and fetal mouse: high expression in the embryonic lung. Biochem Biophys Res Commun 1999; 257:891-89410.1006/bbrc.1999.056210208880Search in Google Scholar

[20] FIEDLER U, SCHARPFENECKER M, KOIDL S, HEGEN A, GRUNOW V, SCHMIDT JM, KRIZ W, THURSTON G, AUGUSTIN HG. The Tie-2 ligand angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies. Blood 2004; 103:4150-425610.1182/blood-2003-10-368514976056Search in Google Scholar

[21] FRIEDL R, LI J, SCHUMACHER B, HANKE H, WALTENBERGER J, HANNEKUM A, STRACKE S. Intimal hyperplasia and expression of transforming growth factor-β1 in saphenous veins and internal mammary arteries before coronary artery surgery. Ann Thorac Surg 2004; 78:1312-131810.1016/j.athoracsur.2004.02.06615464491Open DOISearch in Google Scholar

[22] FRAZIER AA, QURESHI F, READ KM, GILKESON RC, POSTON RS, WHITE CS. Coronary artery bypass grafts: assessment with multidetector CT in the early and late postoperative settings.Radiographics. 2005; 25:881-89610.1148/rg.25404515116009813Open DOISearch in Google Scholar

[23] FUJITA M, IKEMOTO M, KISHISHITA M, OTANI H, NOHARA R, TANAKA T, TAMAKI S, YAMAZATO A, SASAYAMA S. Elevated basic fibroblast growth factor in pericardial fluid of patients with unstable angina. Circulation 1996; 94:610-61310.1161/01.CIR.94.4.610Open DOISearch in Google Scholar

[24] GALE NW, THURSTON G, HACKETT SF, RENARD R, WANG Q, MCCLAIN J, MARTIN C, WITTE C, WITTE MH, JACKSON D, SURI C, CAMPOCHIARO PA, WIEGAND SJ, YANCOPOULOS GD. Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1. Dev Cell 2002; 3:411-42310.1016/S1534-5807(02)00217-4Open DOISearch in Google Scholar

[25] GHOSH J, MURPHY MO, TURNER N, KHWAJA N, HALKA A, KIELTY CM, WALKER MG.The role of transforming growth factor β1 in the vascular system. Cardiovasc Pathol 2005; 14:28-36 10.1016/j.carpath.2004.11.005Open DOISearch in Google Scholar

[26] GRAINGER DJ, KEMP PR, METCALFE JC, LIU AC, LAWN RM, WILLIAMS NR, GRACE AA, SCHOFIELD PM, CHAUHAN A. The serum concentration of active transforming growth factor-beta is severely depressed in advanced atherosclerosis. Nat Med 1995; 1:74-7910.1038/nm0195-74Open DOISearch in Google Scholar

[27] GRAINGER DJ. Transforming growth factor β and atherosclerosis: So far, so good for the protective cytokine hypothesis. Arterioscler Thromb Vasc Biol 2004; 24:399-40410.1161/01.ATV.0000114567.76772.33Open DOISearch in Google Scholar

[28] HASDAI D, BARAK V, LEIBOVITZ E, HERZ I, SCLAROVSKY S, ELDAR M, SCHEINOWITZ M. Serum basic fibroblast growth factor levels in patients with ischemic heart disease. Int J Cardiol 1997; 59:133-13810.1016/S0167-5273(97)02921-5Open DOISearch in Google Scholar

[29] HELDIN CH. Structural and functional studies on platelet-derived growth factor. EMBO J 1992; 11:4251-425910.1002/j.1460-2075.1992.tb05523.x5569971425569Search in Google Scholar

[30] HELDIN CH, WESTERMARK B. Mechanism of action and in vivo role of plateled-derived growth factor. Physiol Rev 1999; 79:1283-131610.1152/physrev.1999.79.4.128310508235Search in Google Scholar

[31] HOLASH H, MAISONPIERRE PC, COMPTON D, BOLAND P, ALEXANDER CR, ZAGZAG D, YANCOPOULOS GD, WIEGAND SJ. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999; 284:1994-199810.1126/science.284.5422.199410373119Search in Google Scholar

[32] HOLMES K, ROBERTS OLL, ANGHARAD MT, CROSS MJ. Vascular endothelial growth factor-2: Structure, function, intracellular signalling and therapeutic inhibition. Cellular Signalling 2007; 19:2003-201210.1016/j.cellsig.2007.05.01317658244Open DOISearch in Google Scholar

[33] HUWER H, WELTER C, ÖZBEK C, SEIFERT M, STRAUB U, GREILACH P, KALWEIT G, ISRINGHAUS H. Simultaneous surgical revascularization and angiogenic gene therapy indiffuse coronary artery disease. Eur J Cardiothorac Surg. 2001; 20:1128-113410.1016/S1010-7940(01)01000-4Open DOISearch in Google Scholar

[34] JONES EL, CRAVER JM, GUYTON RA, BONE DK, HATCHER CR JR, RIECHWALD N.Importance of complete revascularization in performance of the coronary bypass operation. Am J Cardiol 1983; 51:7-1210.1016/S0002-9149(83)80003-4Open DOISearch in Google Scholar

[35] KOHN S, NAGY JA, DVORAK HF, DVORAK AM. Pathways of macromolecular tracer transport across venules and small veins. Structural basis for the hyperpermeability of tumor blood vessels. Lab Invest 1992; 67:596-607Search in Google Scholar

[36] KOYAMA H, NISHIZAWA Y, HOSOI M, FUKUMOTO S, KOGAWA K, SHIOI A, MORII H. The fumagillin analogue TNP-470 inhibits DNA synthesis of vascular smooth muscle cells stimulated by platelet-derived growth factor and insulin-like growth factor-I. Possible involvement of cyclindependent kinase 2. Circ Res. 1996; 79:757-76410.1161/01.RES.79.4.7578831499Search in Google Scholar

[37] KUKK E, LYMBOUSSAKI A, TAIRA S, KAIPAINEN A, JELTSCH M, JOUKOV V, ALITALO K.VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role on lymphatic vascular development. Development 1996; 122:3829-383710.1242/dev.122.12.38299012504Search in Google Scholar

[38] LAHAM RJ, SELLKE FW, EDELMAN AR, PEARLMAN J, WARE A, BROWN DL, GOLD JP, SIMONS M. Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery: results of a phase I randomized, double-blind, placebo-controlled trial. Circulation 1999; 100:1865-187110.1161/01.CIR.100.18.186510545430Open DOISearch in Google Scholar

[39] LAROCHELLE WJ, JEFFERS M, MCDONALD WF, CHILLAKURU RA, GIESE NA, LOKKER NA, SULLIVAN C, BOLDOG FL, YANG M, VERNET C, BURGESS CE, FERNANDES E, DEEGLER LL, RITTMAN B, SHIMKETS J, SHIMKETS RA, ROTHBERG JM, LICHENSTEIN HS. PDGF-D, a new protease-activated growth factor. Nat Cell Biol. 2001; 3:517-52110.1038/3507459311331882Open DOISearch in Google Scholar

[40] LEVIN DC, BECKMANN CF, SOS TA, SNIDERMAN K. Incomplete myocardial reperfusion despite a patent coronary bypass: a generally unrecognized shortcoming of the surgical approach to coronary artery disease. Radiology. 1982; 142:317-32110.1148/radiology.142.2.69765876976587Search in Google Scholar

[41] LI X, PONTEN A, AASE K, KARLSSON L, ABRAMSSON A, UUTELA M, BÄCKSTRÖM G, HELLSTRÖM M, BOSTRÖM H, LI H, SORIANO P, BETSHOLTZ C, HELDIN CH, ALITALO K, OSTMAN A, ERIKSSON U. PDGF-C is a new protease-activated ligand for the PDGF alphareceptor. Nat Cell Biol. 2000; 2:302-30910.1038/3501057910806482Search in Google Scholar

[42] LINDAHL P, JOHANSSON BR, LEVEEN P, BETSHOLTZ C. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 1997; 277:242-24510.1126/science.277.5323.2429211853Open DOISearch in Google Scholar

[43] LOBOV IB, BROOKS PC, LANG RA. Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo. Proc Natl Acad Sci USA 2002; 99:11205-11210 10.1073/pnas.17216189912323412163646Search in Google Scholar

[44] LYTTLE DJ, FRASER KM, FLEMING SB, MERCER AA, ROBINSON AJ. Homologs of vascular endothelial growth factor are encoded by the poxvirus orf virus. J Virol 1994; 68:84-9210.1128/jvi.68.1.84-92.1994Search in Google Scholar

[45] MELDER RJ, KOENIG GC, WITWER BP, SAFABAKHSH N, MUNN LL, JAIN RK. During angiogenesis, vascular endothelial growrh factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium. Nature Med 1996; 2:992-99710.1038/nm0996-992Open DOISearch in Google Scholar

[46] METAIS C, LI J, LI J, SIMONS M, SELLKE FW. Effects of coronary artery disease on expression and microvascular response to VEGF. Am J Physiol Heart Circ Physiol 1998; 275:1411-141810.1152/ajpheart.1998.275.4.H1411Search in Google Scholar

[47] MUKHERJEE D, BHATT DL, ROE MT, PATEL V, ELLIS SG. Direct myocardial revascularization and angiogenesis-how many patients might be eligible? Am J Cardiol 1999; 84:598-60010.1016/S0002-9149(99)00387-2Open DOISearch in Google Scholar

[48] OLOFSSON B, PAJUSOLA K, KAIPAINEN A, VON EULER G, LOUKOV V, SAKSELA O, ORPANA A, PETTERSSON RF, ALITALO K, ERIKSSON U. Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc Natl Acad 1996; 93:2576-258110.1073/pnas.93.6.2576Open DOISearch in Google Scholar

[49] PEPPER MS, FERRARA N, ORCI L, MONTESANO R. Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells. Biochem Biophys Res Commun 1991; 181:902-90610.1016/0006-291X(91)91276-ISearch in Google Scholar

[50] PEPPER MS. Transforming growth factor-β: vasculogenesis, angiogenesis, and vessel wall integrity. Cytokine Growth Factor Rev 1997; 8:21-4310.1016/S1359-6101(96)00048-2Open DOISearch in Google Scholar

[51] PERTOVAARA L, KAIPAINEN A, MUSTONEN T, ORPANA A, FERRARA N, SAKSELA O, ALITALO K. Vascular endothelial growth factor is induced in response to transforming growth factorbeta in fibroblastic and epithelial cells. J Biol Chem. 1994; 269:6271-627410.1016/S0021-9258(17)37365-9Search in Google Scholar

[52] PICHIULE P, CHAVEZ JC, LAMANNA JC. Hypoxic regulation of angiopoietin-2 expression in endothelial cels. J Biol Chem 2004; 279:12171-1218010.1074/jbc.M30514620014702352Search in Google Scholar

[53] POWERS CJ, MCLESKEY SW, WELLSTEIN A. Fibroblast growth factors, their receptors and signaling. Endocr Relat Cancer 2000; 7:165-19710.1677/erc.0.007016511021964Open DOISearch in Google Scholar

[54] ROSENGART TK, LEE LY, PATEL SR, et al. Six-month assessment of a phase I trial of angiogenic gene therapy for the treatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA. Ann Surg 1999; 230: 466-47010.1097/00000658-199910000-00002Search in Google Scholar

[55] ROSS R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362:801-80910.1038/362801a0Search in Google Scholar

[56] RUTHERFORD C, MARTIN W, CARRIER M, ANGGARD EE, FERNS GA. Endogenously elicited antibodies to platelet derived growth factor-BB and platelet cytosolic protein inhibit aortic lesion development in the cholesterol-fed rabbit. Int J Exp Pathol 1997; 78:21-3210.1046/j.1365-2613.1997.d01-237.xSearch in Google Scholar

[57] RUTHERFORD C, MARTIN W, SALAME M, CARRIER M, ANGGARD E, FERNS G. Substantial inhibition of neo-intimal response to balloon injury in the rat carotid artery using a combination of antibodies to platelet-derived growth factor-BB and basic fibroblast growth factor. Atherosclerosis 1997; 130:45-5110.1016/S0021-9150(96)06042-XSearch in Google Scholar

[58] SCHNEIDER H, HUSE K. Arterial gene therapy. Lancet 1996; 348:1380-138210.1016/S0140-6736(05)65442-6Search in Google Scholar

[59] SCHUMACHER B, PECHER P, VON SPECHT BU, STEGMANN T. Induction of neoangiogenesis in ischemic myocardium by human growth factors: first clinical results of a new treatment of coronary heart disease. Circulation 1998; 97:645-65010.1161/01.CIR.97.7.645Open DOISearch in Google Scholar

[60] SEGHEZZI G, PATEL S, REN CJ, GUALANDRIS A, PINTUCCI G, ROBBINS ES, SHAPIRO RL, GALLOWAY AC, RIFKIN DB, MIGNATTI P. Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: an autocrine mechanism contributing to angiogenesis. J Cell Biol 1998; 141:1659-167310.1083/jcb.141.7.1659Search in Google Scholar

[61] SELLKE FW, RUEL M. Vascular growth factors and angiogenesis in cardiac surgery. Ann Thorac Surg 2003; 75:685-69010.1016/S0003-4975(02)04693-3Open DOISearch in Google Scholar

[62] SHWEIKI D, ITIN A, SOFFER D, KESHET E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992; 359:843-84510.1038/359843a01279431Search in Google Scholar

[63] SLAVIN J. Fibroblast growth factors: at the heart of angiogenesis. Cell Biol Int 1995; 19:431-44410.1006/cbir.1995.10877543787Open DOISearch in Google Scholar

[64] SPORN MB, ROBERTS AB, WAKEFIELD LM, DE CROMBRUGGHE B. Some recent advances in the chemistry and biology of transforming growth factor-beta. J Cell Biol. 1987; 105:1039-104510.1083/jcb.105.3.1039Open DOISearch in Google Scholar

[65] TASHIRO H, SHIMOKAWA H, YAMANOTO K, MOMOHARA M, TADA H, TAKESHITA A. Altered plasma levels of cytokines in patients with ischemic heart disease. Coron Artery Dis 1997; 8:143-14710.1097/00019501-199703000-00004Open DOISearch in Google Scholar

[66] THURSTON G. Role of Angiopoietins and Tie receptor tyrosine kinases in angiogenesis and lymphangiogenesis. Cell Tissue Res 2003; 314:61-68 10.1007/s00441-003-0749-6Search in Google Scholar

[67] VALENZUELA DM, GRIFFITHS JA, ROJAS J, ALDRICH TH, JONES PF, ZHOU H, MCCLAIN J, COPELAND NG, GILBERT DJ, JENKINS NA, HUANG T, PAPADOPOULOS N, MAISONPIERRE PC, DAVIS S, YANCOPOULOS GD. Angiopoietins 3 and 4: diverging gene counterparts in mice and humans. Proc Natl Acad Sci USA 1999; 96:1904-190910.1073/pnas.96.5.1904Search in Google Scholar

[68] VEIKKOLA T, KARKKAINEN M, CLAESSON-WELSH L, ALITALO K. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res 2000; 60:203-212Search in Google Scholar

[69] WILSON JM, FERGUSON JJ. Revascularization therapy for coronary artery disease. Coronary artery bypass grafting versus percutaneous transluminal coronary angioplasty. Tex Heart Inst J. 1995; 22:145-161Search in Google Scholar

[70] YAMAZAKI Y, TAKANI K, ATODA H, MORITA T. Snake venom vascular endothelail growth factors (VEGFs) exhibit potent activity through their specific recognition of KDR (VEGF receptor 2). J Biol Chem 2003; 278:51985-5198810.1074/jbc.C300454200Search in Google Scholar

[71] YAMAZAKI Y, MORITA T. Molecular and functional diversity of vascular endothelial growth factors. Divers 2006; 10:515-52710.1007/s11030-006-9027-3Open DOISearch in Google Scholar

[72] YANCOPOULOS GD, DAVIS S, GALE NW, RUDGE JS, WIEGAND SJ, HOLASH J. Vascularspecific growth factors and blood vessel formation. Nature 2000; 407: 242-24810.1038/35025215Search in Google Scholar

[73] ZACHARY I, GLIKI G. Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. Cardiovasc Res 2001; 49:568-581 10.1016/S0008-6363(00)00268-6Open DOISearch in Google Scholar